Proxima fits in a hand. It draws a drop of blood from a fingertip. Twenty minutes later a partial blood count appears on a clinician’s screen. No lab courier. No waiting room. Algocyte, the Oxford-based company behind the device, just cleared a concrete early step toward making that scene routine. Regulatory footing secured The system

The White House has announced fresh measures aimed at restoring manufacturing strength to American soil, with a particular focus on the industrial heartland that once powered the nation’s economy. According to a recent report from Yahoo Finance, these initiatives carry the slogan “Made in Michigan Again” and reflect a broader strategy to revive production capabilities

Cloudflare just dropped the source code for something its own teams have run for months. The company calls it Cloudflare OS. It is not a kernel or a server OS in the classic sense. Instead it is a browser-based workspace where every employee gets an agent that knows the company’s terminology, procedures and systems. Announced

Tim Cook closed out his final earnings call as Apple CEO the way he often did. Calm. Measured. Yet his words carried weight that rippled far beyond Cupertino. On July 30, Cook described the surge in memory costs as a “100-year flood.” He had never used such language in more than four decades in consumer

In a converted warehouse on the outskirts of Nairobi, a dozen young programmers hunch over used laptops. They aren’t chasing the next ChatGPT. They are building chatbots that speak local languages, apps that help smallholder farmers spot crop disease, and legal tools tailored to Kenyan courts. And they do it with Chinese code. Why African

Tech leaders lose sleep over it. A CTO of a major company fields the question on a podcast: Are we still hiring junior engineers? The inquiry lands like a confession. It reveals deep anxiety about artificial intelligence upending software development. Yet the fear rests on shaky ground. Francisco Trindade tackled this head-on in his August

Bank of America CEO Brian Moynihan recently highlighted the substantial financial impact that GLP-1 medications are having on the company’s health care costs. In comments reported by CNBC, Moynihan explained that these drugs, primarily used for treating type 2 diabetes and obesity, have driven up the bank’s overall medical expenses by roughly 15 percent in